CN102382825B - Human miR-1826 antisense nucleic acid and application thereof - Google Patents
Human miR-1826 antisense nucleic acid and application thereof Download PDFInfo
- Publication number
- CN102382825B CN102382825B CN 201010271122 CN201010271122A CN102382825B CN 102382825 B CN102382825 B CN 102382825B CN 201010271122 CN201010271122 CN 201010271122 CN 201010271122 A CN201010271122 A CN 201010271122A CN 102382825 B CN102382825 B CN 102382825B
- Authority
- CN
- China
- Prior art keywords
- mir
- antisense oligonucleotide
- modification
- expression
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an antisense oligonucleotide for inhibiting a micoRNA-1826 expression and an application thereof. The antisense oligonucleotide is specifically combined with human miR-1826, and comprises a sequence which is complementary with at least 13 continuous nucleotides in a 5'-AUUGAUCAUCGACACUUCGAACGCAAU-3' nucleotide sequence, especially the sequence: 5'-AUUGCGUUCGAAGUGUCGAUGAUCAAU-3'. The antisense oligonucleotide disclosed by the invention can be ribonucleotide, deoxyribonucleotide or a chimera of the ribonucleotide and the deoxyribonucleotide, and can modify any one of the nucleotides in a chain. The miR-1826 antisense oligonucleotide disclosed by the invention can effectively inhibit the miR-1826 expression in human brain glioma cells, and inhibit the growth and the proliferation of the human brain glioma cells, so as to effectively treat the brain glioma and other tumours which have the miR-1826 high expression.
Description
Technical field
The present invention relates to biomedicine field.Particularly, the present invention relates to the purposes of a kind of microRNA (miRNA), especially relate to a kind of antisense oligonucleotide and application thereof for suppressing people microRNA-1826 (miR-1826) expression.This antisense oligonucleotide can be complementary with people miR-1826, thereby suppress the expression of people miR-1826 and play antineoplastic action.The invention still further relates to the pharmaceutical composition that contains this miRNA antisense oligonucleotide.
Background technology
MiRNAs is little non-coding RNA, length is 20-28bp, normally transcribed by rna plymerase ii (Pol II), general initial product is the large pri-miRNA with cap sequence (7MGpppG) and polyadenylic acid tail (AAAAA).These pri-miRNA are processed into the pre-miRNA precursor product that 70 Nucleotide form under the effect of RNase III Drosha and its cofactor Pasha.RAN-GTP and exportin 5 are transported to this precursor molecule in the tenuigenin.Subsequently, another RNaseIII Dicer shears it and produces the two strands that is about 22 length of nucleotides.This two strands is directed in (miRISC) complex body very soon, wherein contains Argonaute albumen, and ripe strand miRNA is retained in this mixture.Ripe miRNA is attached to the site of the mRNA complementary with it and expresses by two kinds of machine-processed negative regulator genes that depend on the sequence complementarity, and the miRNA not exclusively complementary with said target mrna suppresses its expression in the protein translation level.Yet, evidence suggests also that recently these miRNA also might affect the stability of mRNA.Use the miRNA binding site of this mechanism usually to hold non-translational region at 3 ' of mRNA.If miRNA and target site complete complementary (perhaps almost completely complementary), the combination of these miRNA often causes the degraded of target molecule mRNA so.MiRNAs is quite conservative in spore, and the miRNAs that finds in animal, plant and fungi etc. expresses all strict tissue specificity and timing.
At present, only have the biological function of very little a part of miRNAs to be elucidated.These miRNAs regulate Growth of Cells and tissue differentiation, and are relevant with biological growth and development.A series of studies show that: miRNAs plays a significant role in the processes such as Growth of Cells and apoptosis, hemocyte differentiation, Homeobox gene adjusting, neuronic polarity, insulin secretion, the formation of brain form, heart generation, late embryogenesis growth.For example, miR-273 participates in the nervous system development process of nematode; MiR-430 participates in the brain development of zebra fish; MiR-181 control Mammals hematopoietic cell is divided into the B cell; MiR-375 regulates mammalian islet cell and grows and insulin secretion; MiR-143 works at Adipocyte Differentiation; MiR-196 has participated in the Mammals four limbs and has formed; MiR-1 is relevant with heart development.Other has the researchist to find that many neural miRNAs are subject to sequential and regulate in pallium is cultivated, and shows the mRNA translation that it may control compartmentation.
MiRNA expresses relevant with kinds cancer, and these genes may play tumor suppressor gene or oncogene effect.In B cell chronic lymphatic leukemia (CLL), find to have at first the change of miRNA expression level, in various human tumors, all detect successively subsequently the variation of miRNA expression level.Research finds, it is relevant that miRNAs and tumour form, and can bring into play the effect (such as miR-15a and miR-16-1) of tumor suppressor gene, can play again the effect (such as miR-155 and miR-17-92 bunch) of oncogene.Think at present, in tumour cell, the ripe body of some miRNA or precursor expression horizontal abnormality, and the miRNA of abnormal expression plays a role by affecting the said target mrna translation, participates in neoplastic process, and plays an important role.Be subjected to the regulation and control of let-7 family such as the Ras proto-oncogene, the BCL2 anti-apoptotic genes expression is subjected to miR-15a-miR-16-1 bunch of regulation and control, and the E2F1 transcription factor is subjected to miR-17-92 bunch of regulation and control, and the BCL6 anti-apoptotic genes expression is subjected to the regulation and control of miR-127 etc.The down-regulated expression of miRNAs also has substantial connection with tumour, and this is indicating that miRNA has the function of oncogene.For example, miR-143 and miR-1826 obviously downward modulation in colorectal carcinoma.What is interesting is that the precursor molecule of its hairpin structure is similar with content in the healthy tissues in tumour, this shows that the down-regulated expression of miRNAs may be because its course of processing is damaged.But the tumor suppressor gene function of miR-143 and miR-1826 may not only be confined to colorectal carcinoma, also obviously downward modulation of its expression amount in the clones such as mammary cancer, prostate cancer, uterus carcinoma, lymphatic cancer.Another report shows that miR-21 expresses increase in glioblastoma multiforme.The expression amount of this gene in tumor tissues than high 5-100 in healthy tissues doubly.
MiRNAs is natural antisense acting factor, can regulate and control the several genes relevant with propagation with eukaryote existence.Aspect oncotherapy, the application prospect of miRNA is bright.Utilizing miRNA as aspect the treatment target spot, existing experimental data support: as in the process of gemcitabine (gemcitabine) treatment, the variation of miRNA express spectra occurs; The expression level (as making miR-21 cross expression) of regulation and control part miRNA can be promoted cholangiocarcinoma cell to the susceptibility of chemotherapeutics.By introducing and the effective miRNAs in the deactivation tumour of the synthetic antisense oligonucleotide---anti-miRNA oligonucleotide (AMOs)---of the miRNA complementation with oncogene characteristic, delay its growth.Clinically, can methylate or the antisense oligonucleotide administration of locking the modifications such as nucleic acid (LNA) makes the miRNA inactivation by 2 '-O-frequent or that continue.These modifications are so that oligonucleotide is more stable, and are lower than other treatment means toxicity.Use antagomirs (with the AMOs of cholesterol coupling), can be active at Different Organs establishment miRNA behind the injection mouse, thereby may become a kind of medicine likely.Opposite, cross and express the miRNAs that those have the tumor suppressor gene effect, such as let-7 family, also can be used for the treatment of some specific tumour.
Antisense oligonucleotide (Flanagan WM.Antisense comes of age.Cancer﹠amp; Metastasis Reviews 1998; 17 (2): 169-76) refer to one section can with the Nucleotide of the base complementrity of its target gene.Antisense oligonucleotide can suppress the expression of corresponding gene.
People microRNA-1826 (hsa-mir-1826) is positioned at karyomit(e) No. 16, precursor sequence is AUUGAUCAUCGACACUUCGAACGCAAUUGCAGCCCGGGUUCCUCCCAGGGCUUUGC CUGUCUGAGCGUCGCUUGCCGAUCAGUAG, only contains a ripe microRNA:hsa-miR-1826 (sequence is AUUGAUCAUCGACACUUCGAACGCAAU).
The people such as Zhou are utilizing microarray research 5-FU and oxaliplatin (L-OHP) on colon cancer cell line impact discovery, and miR-1826 is downward modulation (Zhou, J., Y.Zhou, et al.2009) after giving anticarcinogen.In other tumours, also do not report about the function of miR-1826 and the research of expression level.
Nearly 30 years, although the complex therapy of tumour is very general clinically, but take operation as main, to be auxiliary complex therapy improve and not obvious the survival rate of tumour patient chemicotherapy, overall survival rate was still lower in 5 years, paced up and down about 30%～55%, did not significantly improve, 5 years survival rates of middle and advanced stage patient are lower, are about 20%.And all there are limitation separately in these methods, particularly to middle and advanced stage and patients with recurrent unsatisfactory curative effect, to poorer with distant metastasis person's curative effect.Therefore, seeking safer and more effective treatment approach is the difficult problem that raising tumour patient survival rate and life quality need to be resolved hurrily.
Summary of the invention
The subject matter that the present invention will solve just provides the antisense oligonucleotide (inhibitor) of a kind of new miR-1826, be used for efficient, low toxicity or suppress innocuously the expression of miR-1826, and then the treatment disease relevant with the miR-1826 overexpression, comprise various noumenal tumours, various leukemia etc.
Another problem that the present invention will solve just provides the purposes of above-mentioned antisense oligonucleotide in the medicine of the relative disease of preparation treatment miR-1826 overexpression.
The again problem that the present invention will solve provides the pharmaceutical composition that comprises above-mentioned antisense oligonucleotide.
The inventor has designed and synthesized the antisense nucleic acid oligomer of a species specificity for miR-1826 by extensive and deep research, and checking has the miR-1826 of inhibition expression and cytostatic effect in culturing cell.Studies show that growth and malignant proliferation ability that these antisense nucleic acides can inhibition tumor cell.
The present invention designed a kind of can specific binding in the antisense nucleic acid molecule of miR-1826, in culturing cell U87/MG, the antisense nucleic acid cell growth ability that checking suppresses the miR-1826 expression specificity, the impact of multiplication capacity.Antisense nucleic acid molecule length can comprise 13～27 nucleotide residues, inhibition growth of human tumor cells ability in various degree, the characteristic of multiplication capacity are all arranged, wherein the shortest antisense nucleic acid length is 13 bases, and the antisense nucleic acid of different lengths all has good growth of tumour cell and proliferation inhibition activity.Therefore, above-mentioned antisense nucleic acid all can be used to prepare the preparation of inhibition tumor cell energy for growth, multiplication capacity, wherein the tumour cell of preferred miR-1826 high expression level.Finished on this basis the present invention.
A first aspect of the present invention provides the antisense oligonucleotide of a kind of miR-1826, and described antisense oligonucleotide suppresses the expression of miR-1826 in people's cell.Usually, continuous 13～27 nucleotide sequence complementations among described antisense oligonucleotide and the 5 '-AUUGAUCAUCGACACUUCGAACGCAAU-3 '.In a preferred embodiment of the invention, the length of described antisense oligonucleotide is 18～23 Nucleotide.More preferably, the sequence of described antisense oligonucleotide is 5 '-AUUGCGUUCGAAGUGUCGAUGAUCAAU-3 '.
At present, RNA is higher than the avidity of DNA and miRNA hybridization with the hybridization avidity of miRNA in the nucleic acid hybridization, has very high pharmaceutical use.But artificial-synthetic DNA's the cost far away cost than synthetic RNA is low, also has good market potential.And can adopt the chimeric antisense nucleic acid that forms that links to each other of ribose RNA monomer and ribodesose dna single body to develop as medicine.A series of antisense oligonucleotide molecules of the present invention's design both can be DNA, also can be RNA, can also be the mosaics of DNA and RNA.Above-mentioned molecule all has the activity that suppresses the miR-1826 expression.
The antisense nucleic acid of the present invention's design, it is active that its sequence has specific biological, it has much relations for the complementary length of the antisense nucleic acid in the site of a certain gene complementation, length such as complementation is a little, then biologic activity can be higher, and inhibition also can be more better, increasing or reducing an antisense nucleic acid that is complementary to the same gene site to several bases, equally also have biologic activity in various degree, also can reach in various degree inhibition tumor cell growth and the effect of breeding.Of the present invention studies show that the shortlyest reaches 13 bases and still has the effect that miR-1826 expresses that suppresses.In the antisense nucleic acid research, various chemical modification methods are a lot.The present invention adopts the antisense nucleic acid of the one or more combination modification that is selected from ribose modification, base modification and the phosphoric acid backbone modification, the preclinical studies such as the pharmacology of the antisense nucleic acid of sulfo-, methoxy modification mode, pharmacokinetics, toxicology are that research is the most comprehensive in the various chemically modified antisense nucleic acides, the antisense nucleic acid of modifying can prevent effectively in vivo in the human body that a large amount of exonucleases cut the enzyme of antisense nucleic acid and degrade, thereby avoids antisense nucleic acid to lose due biologic activity.The sulfo-antisense nucleic acid also can excite the activity of RNA enzyme in addition, the RNA chain that degraded is hybrid with it, and therefore preferred these the two kinds antisense nucleic acides of modifying mode are used in experiment.Will be clear that any modifying method that can increase antisense nucleic acid stability and bioavailability can use, as cholesterol modify, PEG modification etc.Antisense nucleic acid preferred of the present invention is modified one or more that are selected from thio-modification, 2 '-methoxyl group modification and the cholesterol modification.Most preferably adopt following modification mode: all Nucleotide carry out 2 '-methoxyl group to be modified, and two Nucleotide of 5 ' end carry out thio-modification, and four Nucleotide of 3 ' end carry out thio-modification and connect cholesterol at 5 ' or 3 ' end.
Above-mentioned antisense nucleic acid of the present invention has the effect that suppresses the miR-1826 expression.After in above-mentioned antisense nucleic acid being transfected into the cell strain U87/MG that expresses miR-1826, growth and malignant proliferation ability that can establishment U87/MG cell.
The present invention also provides a kind of pharmaceutical composition, and it contains oligonucleotide of the present invention and pharmaceutically acceptable carrier or the vehicle of safe treatment significant quantity.This class drug administration carrier includes but not limited to the various carriers that can be used for the nucleic acid administration, such as liposome, degradable macromolecular compound, salt solution, damping fluid, glucose, water, glycerine, ethanol and combination thereof.Pharmaceutical preparation should be complementary with administering mode.
Described " significant quantity " refers to and can produce function or amount active and that can be accepted by people and/or animal to people and/or animal.
Described " pharmaceutically acceptable " composition is applicable to people and/or animal and without excessive bad side reaction (such as toxicity, stimulation and transformation reactions), the material of rational benefit/risk ratio is arranged namely.
In a third aspect of the present invention, the purposes of antisense oligonucleotide of the present invention is provided, medicine for the preparation of the following disease for the treatment of: the treatment human body is crossed with miR-1826 and is expressed relevant disease, comprises various noumenal tumours (particularly cerebral glioma), various leukemia etc.
As used herein, " antisense oligonucleotide " refers to the nucleotide oligomer of antisense.Antisense oligonucleotide is by base complementrity (A-T, A-U, G-C) pairing forms three chains (anti-gene) with double-stranded DNA, or forms heteroduplex (antisense) with single stranded RNA, thus the processing and the translation that copy, transcribe or transcribe rear mRNA of blocking gene.Simultaneously, double-stranded RNA can be degraded by intracellular ribonuclease H (RNaseH), thereby more effectively blocks the expression of target gene.Because antisense nucleotide can only be combined with the target sequence of reverse complemental, has the specificity height, the characteristics that side effect is little.
The length of antisense oligonucleotide of the present invention is not particularly limited, and in general, in order to reach the specificity of hybridization, antisense oligonucleotide needs the Nucleotide of at least 13 monomer compositions.Usually the length of antisense oligonucleotide is 13～35bp, and for miRNA, that better is 18～27bp.
Description of drawings
Fig. 1 has shown the expression of miR-1826 in the miR-1826 antisense oligonucleotide inhibition tumor cell U87/MG cell, and three lines are results of revision test among Figure 1A～D.A is the expression of miR-1826 behind the transfection miR-1826 antisense oligonucleotide (5 '-AUUGCGUUCGAAGUGUCGAUGAUCAAU-3 '), and B is the expression of miR-1826 behind the transfection negative control antisense oligonucleotide (5 '-CAGUACUUUUGUGUAGUACAA-3 '); C is the expression that turns reference gene U6 behind the miR-1826 antisense oligonucleotide; D is the expression of reference gene U6 behind the transfection negative control antisense oligonucleotide; E is miR-1826 inhibition histogram behind the transfection antisense oligonucleotide, X-coordinate is the sample that detects, the miR-1826 expression behind " inhibitor " expression transfection miR-1826 antisense oligonucleotide wherein, miR-1826 expression behind " negative control " expression transfection negative control.
Fig. 2 has shown growth and the propagation of miR-1826 antisense oligonucleotide inhibition tumor cell U87/MG cell, the U87/MG cell behind A, B the have been transfection negative control of FAM mark; C is U87/MG cell state behind the transfection negative control; D is U87/MG cell state behind the transfection miR-1826 antisense oligonucleotide (5 '-AUUGCGUUCGAAGUGUCGAUGAUCAAU-3 ').
Embodiment
Antisense oligonucleotide of the present invention, continuous 13～27 nucleotide sequence complementations among its sequence and 5 '-AUUGAUCAUCGACACUUCGAACGCAAU-3 ', and also not complementary with the RNA sequence of other genes.In a preferred embodiment of the invention, the sequence of described antisense oligonucleotide is 5 '-AUUGCGUUCGAAGUGUCGAUGAUCAAU-3 '.Antisense oligonucleotide provided by the invention can be modified outcome, it contains at least two, and at least 4 usually, better at least 6, at least 8 better Nucleotide do not have the Nucleotide of the modification of toxic side effects, and described modification mode comprises 2 '-position methoxy substitution, thio-modification etc.In order to increase the cellular uptake rate of antisense oligonucleotide, can also on the basis of above-mentioned modification, carry out cholesterol to antisense oligonucleotide and modify or the PEGization modification.Oligonucleotide after the above-mentioned modification can continue effectively to match with target sequence, and has in vivo the longer transformation period than common not modified Yeast Nucleic Acid or thymus nucleic acid.
The present invention has following advantage:
1, antisense oligonucleotide acts on specific target site, the site of non-specific binding seldom, specificity is high;
2, antisense oligonucleotide provided by the invention is through suitable chemically modified, has that toxicity is low, side effect is little and the characteristics such as long half time;
3, antisense oligonucleotide provided by the invention has good inhibition, the inhibiting rate of the expression of miR-1826 is reached more than 95%, to the inhibiting rate of growth of tumour cell near 40%.
Below in conjunction with embodiment and accompanying drawing the present invention is described in further detail.Yet should be appreciated that and enumerate these embodiment just for an illustration, and be not to limit the scope of the invention.
Embodiment
At first, by Shanghai JiMa pharmacy Technology Co., Ltd's synthetic antisense oligonucleotide, sequence is: 5 '-AUUGCGUUCGAAGUGUCGAUGAUCAAU-3 '.The used sequence that relates in an embodiment is synthetic by Shanghai JiMa pharmacy Technology Co., Ltd.
Carry out real-time quantitative fluorescence and detect, the oligonucleotide sequence that wherein relates to is synthetic by Shanghai JiMa pharmacy Technology Co., Ltd, and concrete experimental procedure comprises:
Cell cultures: U87/MG cell (available from typical case's culture collection council of Chinese Academy of Sciences cell bank), 10%FBS-DMEM substratum (FBS is available from Hyclone, and DMEM is available from Gibco) is cultivated, and 37 ℃, 5%CO
2Cultivate.
Cell transfecting:
1) transfection the day before yesterday, with not containing in right amount antibiotic culture medium inoculated culturing cell, the degree of converging of cell reaches 30～50% when making transfection in 24 orifice plates;
2) the transfection sample is prepared oligomer-Lipofecta mine as follows
TM2000 mixtures:
A. do not contain serum with 50 μ l
Substratum (Gibco) dilutes respectively the negative control of miR-1826 antisense oligonucleotide (5 '-AUUGCGUUCGAAGUGUCGAUGAUCAAU-3 '), negative control (5 '-CAGUACUUUUGUGUAGUACAA-3 '), FAM mark, final concentration is 50nM, mixing gently, each transfection are established 3 multiple holes;
B. mixing Lipofecta mine gently before using
TM2000 (Invitrogen) then get 2 μ l and are diluted to 50 μ l's
In the substratum, at room temperature hatch gently 5min behind the mixing;
C. after hatching 5min, the Lipofecta mine of dilution
TM2000 mix with antisense nucleotide and the contrast of dilution respectively, at room temperature hatch gently 20min behind the mixing, to allow complex formation;
3) mixture is joined in each hole that comprises cell and substratum, the culture plate that rocks back and forth lightly mixes;
4) 37 ℃, 5%CO
2The incubator overnight incubation is changed the substratum that contains 10% foetal calf serum and is continued to cultivate 24h.
Total RNA extracts:
1) centrifugal collecting cell adds 500 μ l Ezol (Invitrogen) in the centrifuge tube, and with the centrifuge tube mixing that turns upside down, room temperature is placed 10min.
2) trichloromethane of adding 200 μ l RNA special uses (worker is given birth in Shanghai), the mixing that acutely turns upside down is until the thorough mixing of the liquid in the centrifuge tube becomes the oyster white shape.
3) room temperature is placed 5min, the centrifugal 15min of 12000rpm.
4) carefully supernatant is transferred in another clean 1.5ml centrifuge tube, avoids inhaling middle level albumen phase and lower floor's organic phase.
5) add the Virahol (worker is given birth in Shanghai) of the RNA special use of 500 μ l precoolings in the supernatant, room temperature is placed 5min.The centrifugal 10min of 10000rpm.
6) carefully abandon most supernatant, add 75% ethanol (worker is given birth in Shanghai) washing precipitation of 1ml RNA special use, the centrifugal 10min of 10000rpm.
7) carefully abandon most supernatant, place room temperature to dry ethanol, every pipe adds 20 μ l DEPC water dissolution, mixing.
The RNA reverse transcription:
The RNA that above-mentioned extracting is obtained carries out reverse transcription with U6 and two kinds of special reverse transcriptase primers of RNA of hsa-miR-1826 respectively, preparation cDNA template.Damping fluid and enzyme used in the reverse transcription are Promega company product; Primer sequence is synthetic by Shanghai JiMa pharmacy Technology Co., Ltd, miR-1826RT primer: 5 '-GTCGGGTCCAGAGCAGGGTCCGAGGTACACGTTCGCTCTGGACCCGACATTGCGTT CG-3 '.
(i). the reverse transcription system:
(ii). the reverse transcription reaction condition:
Reaction conditions is: 26 ℃ of 30min; 42 ℃ of 30min; 85 ℃ of 10min.
Fluorescence quantitative PCR detection:
(1) dilution of .cDNA template:
The cDNA that obtains behind the above-mentioned reverse transcription is diluted 3 times, in the system of 20 μ l, add 40 μ l without the ddH of RNase/DNase
2O, mixing.
(2). (primer sequence is synthetic by Shanghai JiMa pharmacy Technology Co., Ltd for the quantitative fluorescent PCR system; MiR-1826FP primer: 5 '-TCCGCATTGATCATCGACA-3 '; MiR-1826RP primer: 5 '-CAGAGCAGGGTCCGAGGTA-3 '):
| Reagent name | Consumption/ |
| 2×PCR Master Mix | 10μl |
| F Primer(20μM) | 0.2μl |
| R Primer(20μM) | 0.2μl |
| Template | 2μl |
| RTaq archaeal dna polymerase (5U/ul) | 0.2μl |
| ddH 2O | Add to 20 μ l |
(3). reaction conditions:
(i)95℃3min；
(ii)95℃30s；
(iii)62℃40s；
(iv)72℃30s；
Ii to the iv goes on foot totally 40 circulations.
Fluorescence quantitative PCR detection result shows that antisense oligonucleotide has good inhibition.Fig. 1 has shown the expression of miR-1826 in the miR-1826 antisense oligonucleotide inhibition tumor cell U87/MG cell, and three lines are results of revision test among Figure 1A～D.A is the expression of miR-1826 behind the transfection miR-1826 antisense oligonucleotide (5 '-AUUGCGUUCGAAGUGUCGAUGAUCAAU-3 '), and B is the expression of miR-1826 behind the transfection negative control antisense oligonucleotide (5 '-CAGUACUUUUGUGUAGUACAA-3 '); C is the expression that turns reference gene U6 behind the miR-1826 antisense oligonucleotide; D is the expression of reference gene U6 behind the transfection negative control antisense oligonucleotide; E is miR-1826 inhibition histogram behind the transfection antisense oligonucleotide, X-coordinate is the sample that detects, the miR-1826 expression behind " inhibitor " expression transfection miR-1826 antisense oligonucleotide wherein, miR-1826 expression behind " negative control " expression transfection negative control.The result shows that antisense oligonucleotide has obvious restraining effect to the expression of miR-1826.
The oligonucleotide sequence that wherein relates to is synthetic by Shanghai JiMa pharmacy Technology Co., Ltd.
Cell cultures:
U87/MG cell (available from typical case's culture collection council of Chinese Academy of Sciences cell bank), 10%FBS-DMEM substratum (FBS is available from Gibco, and DMEM is available from Hyclone) is cultivated, and 37 ℃, 5%CO
2Cultivate.Collect the good U87/MG cell of growth conditions, centrifugal counting is with 2 * 10
3Every hole is laid in 96 orifice plates, and 37 ℃, 5%CO
2Cultivate 24h.
Transfection:
1) transfection the day before yesterday, with not containing in right amount antibiotic culture medium inoculated culturing cell, the degree of converging of cell reaches 30～50% when making transfection in 96 orifice plates;
2) the transfection sample is prepared oligomer-Lipofecta mine as follows
TM2000 mixtures:
A. do not contain serum with 25 μ l
Substratum (Gibco) dilutes respectively the negative control of miR-1826 antisense oligonucleotide (5 '-AUUGCGUUCGAAGUGUCGAUGAUCAAU-3 '), negative control (5 '-CAGUACUUUUGUGUAGUACAA-3 '), FAM mark, final concentration is 50nM after adding in the hand-hole, mixing gently, each transfection are established 3 multiple holes;
B. mixing Lipofecta mine gently before using
TM2000 (Invitrogen) then get 0.25 μ l and are diluted to 25 μ l's
Substratum is at room temperature hatched 5min gently behind the mixing;
C. after hatching 5min, the Lipofecta mine of dilution
TM2000 mix with antisense nucleotide and the contrast of dilution respectively, at room temperature hatch gently 20min behind the mixing, to allow complex formation;
3) mixture is joined in each hole that comprises cell and substratum, the culture plate that rocks back and forth lightly mixes; The final concentration of antisense nucleotide and contrast is 50nM.
4) 37 ℃, 5%CO
2After incubator continued to hatch 72 hours, microscopic examination U87/MG cell was taken a picture.
As shown in Figure 2, transfection is after 72 hours, surpassed 80% U87/MG cell success transfection the negative control of FAM mark (figure A, B); Behind the transfection negative control, the U87/MG cell is complete, light transmission strong (figure C); And most of U87/MG necrocytosis behind the transfection miR-1826 antisense oligonucleotide (figure D).
Cytotoxicity experiment based on MTT:
The cell that obtains in the previous step adds MTT (Sigma) 5mg/ml (physiological saline with 0.9% is prepared) for preparing, and every hole adds 20 μ l, 37 ℃, 5%CO
2Hatch after 4 hours and suck substratum and MTT, every hole adds DMSO 100 μ l and reads the absorbance of OD570-OD630 by microplate reader:
Calculate inhibiting rate:
Calculating the miR-1826 antisense oligonucleotide is that inhibitory rate of cell growth is 38.76 ± 11.53% to the neuroglia cell of human oncocyte.The result shows: miR-1826 antisense oligonucleotide provided by the invention has good inhibition, to the inhibiting rate of U87/MG growth near 40%.MiR-1826 antisense oligonucleotide of the present invention can the establishment human glioma cell in miR-1826 express, suppress its growth and propagation, thereby effectively treat the tumour of cerebral glioma and other miR-1826 high expression levels.
Claims (6)
1. an antisense oligonucleotide is for the preparation of the purposes of the medicine for the treatment of cerebral glioma, wherein, described antisense oligonucleotide sequence is the chimeric sequence with ribonucleoside acid sequence, deoxyribonucleotide sequence or ribonucleotide and the deoxyribonucleotide of the complementation of 5 '-AUUGAUCAUCGACACUUCGAACGCAAU-3 ' nucleotide sequence.
2. purposes as claimed in claim 1 is characterized in that, described antisense oligonucleotide sequence is 5 '-AUUGCGUUCGAAGUGUCGAUGAUCAAU-3 '.
3. purposes as claimed in claim 1 or 2 is characterized in that, described antisense oligonucleotide is further modified.
4. purposes as claimed in claim 3 is characterized in that, described modification is selected from one or more the combination in ribose modification, base modification and the phosphoric acid backbone modification.
5. purposes as claimed in claim 4 is characterized in that, described modification is selected from one or more in thio-modification, 2 '-methoxyl group modification and the cholesterol modification.
6. purposes as claimed in claim 5 is characterized in that, all Nucleotide carry out 2 '-methoxyl group to be modified, and two Nucleotide of 5 ' end carry out thio-modification, and four Nucleotide of 3 ' end carry out thio-modification and connect cholesterol at 5 ' or 3 ' end.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010271122 CN102382825B (en) | 2010-09-01 | 2010-09-01 | Human miR-1826 antisense nucleic acid and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010271122 CN102382825B (en) | 2010-09-01 | 2010-09-01 | Human miR-1826 antisense nucleic acid and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102382825A CN102382825A (en) | 2012-03-21 |
| CN102382825B true CN102382825B (en) | 2013-02-27 |
Family
ID=45822657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010271122 Active CN102382825B (en) | 2010-09-01 | 2010-09-01 | Human miR-1826 antisense nucleic acid and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102382825B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113201544A (en) * | 2021-05-20 | 2021-08-03 | 大连海洋大学 | miR-210 simulant, preparation method and application of miR-210 simulant as antibiotic substitute for breeding |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8222221B2 (en) * | 2008-06-04 | 2012-07-17 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small RNA targeting of gene promoters |
| CN101507821A (en) * | 2009-03-20 | 2009-08-19 | 天津医科大学总医院 | Medicine for treating malignant cerebroma and breast cancer by combining gene and chemotherapy medicine and preparation method thereof |
-
2010
- 2010-09-01 CN CN 201010271122 patent/CN102382825B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102382825A (en) | 2012-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102080086B (en) | Human miR-133a antisense nucleic acid and application thereof | |
| CN102382824A (en) | Human miR-145 antisense nucleic acid and application thereof | |
| CN102031256B (en) | Human miR-485-5p antisense nucleic acid and application thereof | |
| CN102140468A (en) | Human miR-185* antisense nucleic acid and application thereof | |
| CN102533755A (en) | Human miR-328 antisense nucleic acid and application thereof | |
| CN102080083B (en) | Human miR-149 antisense nucleotide and application thereof | |
| CN102140469B (en) | Human miR (microRNA)-1233 antisensenucleic acid and application thereof | |
| CN102080085B (en) | Human miR-193b antisense nucleotide and application thereof | |
| CN102080082B (en) | Human miR-129* antisensenucleic acid and applications thereof | |
| CN102031254B (en) | Human miR-150 antisense nucleic acid and application thereof | |
| CN102382825B (en) | Human miR-1826 antisense nucleic acid and application thereof | |
| CN102140462B (en) | Human miR-1260 antisense nucleic acid and application thereof | |
| CN102140467B (en) | Human miR-365 antisense nucleic acid and application thereof | |
| CN102140470B (en) | Human miR-1236 antisense ribonucleic acid and application thereof | |
| CN102140465B (en) | Human miR-1249 antisense nucleic acid and application thereof | |
| CN102031255B (en) | Antisense nucleic acid of human miR-223 and applications of antisense nucleic acid | |
| CN102140464B (en) | Human miR-1238 antisense nucleic acid and applications thereof | |
| CN102382823B (en) | Human miR-515-5p antisense oligod-eoxynucleotide and applications thereof | |
| CN102080084B (en) | Human miR-125a-5p antisense nucleotide and application thereof | |
| CN102643807B (en) | Antisense oligodeoxyncleotide of human miR-484 and application thereof | |
| CN102643813B (en) | The antisense oligonucleotide of people miR-504 and application thereof | |
| CN102140466B (en) | Human miR-1825 antisense nucleic acid and application thereof | |
| CN102041256B (en) | Human miR-486-5p antisense nucleic acid and application thereof | |
| CN102643810A (en) | Human miR-299-5p antisense oligonucleotide and application thereof | |
| CN102643809A (en) | Antisense oligodeoxyncleotide of human miR-1274b and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |